

1 **A mixed methods evaluation of 99DOTS digital adherence technology uptake among**
2 **adolescents treated for pulmonary tuberculosis in Uganda.**

3 Wambi P^{1*}, West N.S.^{2,3*}, Nabugoomu J¹, Kityamuwesi A¹, Crowder R², Kunihiro L¹, Wobudeya
4 E^{1,4}, Cattamanchi A^{1,3,5}, Jaganath D^{2,3,6**}, Katamba A^{1,7**}

5
6 * Contributed equally as first authors

7 ** Contributed equally as senior authors

8 ¹Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.

9 ²Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University
10 of California San Francisco, San Francisco, California, USA.

11 ³Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.

12 ⁴Mulago National Referral Hospital, Uganda.

13 ⁵Division of pulmonary diseases and Critical Care Medicine, University of California Irvine,
14 Irvine, California, USA.

15 ⁶Division of Pediatric Infectious Diseases, University of California San Francisco, San Francisco,
16 California, USA.

17 ⁷Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University
18 College of Health Sciences, Kampala, Uganda.

19 ABSTRACT

20 **Introduction:** Adolescents and young adults are at risk of poor adherence to tuberculosis (TB)
21 treatment and subsequently worse TB treatment outcomes. Digital adherence technologies,
22 including the mobile phone-based 99DOTS platform, can support TB treatment, but there is
23 limited data on their use among adolescents.

24 **Objective:** To evaluate factors associated with the uptake of 99DOTS among adolescents with
25 TB.

26 **Methods:** We conducted an explanatory sequential mixed methods study that utilized quantitative
27 data from adolescents collected during the scale-up of 99DOTS at 30 health facilities in Uganda,
28 and qualitative in-depth and key informant interviews with a subset of adolescents with pulmonary
29 TB offered 99DOTS and healthcare providers at participating facilities. Findings were further
30 mapped onto the Capability, Opportunity, Motivation, and Behavior (COM-B) model.

31 **Results:** Overall, 299/410 (73%) eligible adolescents were enrolled in 99DOTS. Older adolescents
32 15 to 19 years old were more likely to enroll in 99DOTS than younger adolescents 10 to 14 years
33 [aPR= 0.56, 95% CI: (0.42-0.73)]. Conversely, adolescents treated at Health Center IV and
34 General Hospitals were less likely to be enrolled compared to Health Center III (aPR= 0.8, 95%
35 CI, 0.67-0.94, and aPR=0.71, 95% CI 0.58-0.85, respectively). Technological savviness among
36 older adolescents, access to training, caregiver or treatment supporter involvement, and desire for
37 wellness facilitated the uptake of 99DOTS. In contrast, variable mobile phone access, concerns
38 about TB status disclosure, and health worker workload in hospitals were barriers to the uptake of
39 99DOTS.

40 **Conclusion:** 99DOTS uptake was high among adolescents with TB. Increased access to mobile
41 phones, health worker training on adolescent communication, and more involvement of caregivers
42 could facilitate greater use of 99DOTS and similar technologies.

43 **Introduction**

44 Tuberculosis (TB) is the leading infectious disease cause of death worldwide (1). Among 10.6
45 million people who became ill with TB in 2022, an estimated 1.8 million are adolescents and young
46 adults -ages 10-24 years (1). Adolescents have unique social and biological determinants that
47 increase their risk of TB treatment adherence challenges (2, 3) and subsequent poor treatment
48 outcomes as compared to adults and children (4, 5). However, adolescents are often overlooked as
49 a unique population in TB and are frequently grouped with children or adults (6), limiting the
50 development of adolescent-specific interventions.

51 Uganda ranks top among high-prevalence TB countries worldwide, with an estimated incidence
52 of 198 per 100,000 population (7). Adolescents and young adults aged 15 to 24 years account for
53 approximately 13% of TB disease in the country, with treatment success rates varying between
54 50% and 85% depending on the region (7). A study in Uganda found that adolescents with TB
55 were twice as likely to be lost to follow-up compared to children under five years, when receiving
56 standard community-based directly observed therapy (CB-DOT) (5). Further, non-adherence to
57 TB treatment and risk of loss of follow-up are persistently higher among HIV-TB co-infected
58 adolescents (8).

59 Globally, there is increasing advocacy for investing in and using digital adherence technologies
60 (DATs) within National TB Programs (NTPs) to provide remote treatment support and monitoring
61 for people with TB (Stop TB Partnership 2019). In 2017, the World Health Organization (WHO)
62 recommended the use of information technologies to improve TB treatment outcomes (9). The
63 Uganda National TB Leprosy Program has further prioritized using digital technologies to tackle
64 the challenge of poor treatment adherence and improve treatment outcomes among all patients,

65 including adolescents (10). Recent studies have shown promising results with these technologies
66 for adherence among adults in Uganda (11-13).

67 99DOTS is a DAT that utilizes low-end mobile phones (i.e. not smart phones) for patients and a
68 web-based dashboard and mobile phone application for healthcare workers. It consists of
69 automated SMS dosing reminders, daily reporting of dose completion by calling a random toll-
70 free telephone number on TB medication blister packs, and weekly automated interactive voice
71 response check-in phone calls. Clinic staff can view real-time adherence data for each patient via
72 the mobile app and web dashboard. In the DOT to DAT stepped-wedged cluster randomized trial
73 in Uganda, we found that 99DOTS was highly feasible and acceptable among adults with
74 pulmonary TB (13-15), and achieved high treatment completion (12).

75 Beginning in 2021, the 99DOTS intervention was scaled up to 30 health facilities across Uganda,
76 including the health facilities previously enrolled in the DOT to DAT trial, and became available
77 also to adolescents. The objective of this study was to use sequential explanatory mixed methods
78 to evaluate the factors associated with the uptake of the 99DOTS intervention among adolescents
79 on treatment for drug-susceptible pulmonary TB (DS-PTB) treatment in Uganda.

80 **RESULTS**

81 **PHASE I: QUANTITATIVE**

82 **Socio-demographic characteristics of study participants**

83 A total of 410 adolescents with TB were included. The median age was 17 years (IQR 14-18),
84 59% (n=241) were female; 20% (n=82) were living with HIV, 60% (n=246) had microbiologically
85 confirmed TB, and 75.8% had at least one treatment supporter (Table 1).

86

87 **Table 1: Overall socio-demographic and clinical characteristics (n=410)**

	Variable	Frequency (%)
Age	10-14	129 (31.5%)
	15-19	281 (68.5%)
Sex	Female	241 (58.8%)
	Male	169 (41.2%)
Disease Classification	Confirmed TB	246 (60.0%)
	Clinically Diagnosed TB	164 (40.0%)
HIV Status	HIV Negative	326 (79.5%)
	HIV Positive	82 (20.5%)
Treatment support	Yes	311 (75.8%)
	No	46 (11.2%)

88

89 **Uptake of 99Dots**

90 Overall, 299 (73%) were enrolled in 99DOTS during the study period. Of the study participants
 91 enrolled on 99DOTS, higher uptake was seen among older adolescents (15-19 years), females,
 92 those who had confirmed TB, adolescents who had a caretaker, and those who were enrolled at
 93 lower-level health centers and regional referral hospitals (Table 2). The adjusted prevalence of
 94 uptake of 99DOTS was higher among older (15-19 years) than younger (10-14 years) adolescents
 95 (aPR 1.88 95% CI: 1.54-2.33) (Table 3) and adolescents who had a treatment supporter (*i.e.*,
 96 family member who was their caretaker) (aPR 1.44, 95% CI: 1.13- 1.83). The adjusted prevalence
 97 of uptake of 99DOTS was lower among adolescents treated at either Health Center IVs (aPR 0.8,
 98 95% CI: 0.67-0.94) or General Hospitals (aPR = 0.71, 95% CI: 0.58-0.85) compared to adolescents
 99 treated at Health Center IIIs (Table 2).

100

101 **Table 2: Uptake of 99DOTS stratified by Age, Sex, Disease classification, HIV status,**
 102 **treatment support, and level of care.**

Variable		Frequency	Uptake of 99DOTS	Unadjusted PR p-value	95% CI, Adjusted PR 95% CI, p-value
Age	10-14 Years	129 (31.5%)	60 (47%)	1.0	1.0
	15-19 Years	281 (68.5%)	238 (85%)	1.79 (1.36 - 2.38), < 0.001	1.88 (1.54-2.33), < 0.001
TB Classification	Confirmed	246 (60%)	196 (80%)	1.0	1.0
	Clinically diagnosed	164 (40%)	103 (63%)	0.78 (0.7-1.02), 0.051	0.91 (0.8-0- 1.04), 0.21
HIV status	HIV Negative	326 (79.5%)	238 (73%)	1.0	1.0
	Positive	82 (20.5%)	60 (73%)	1.00 (0.75- 1.3), 0.98	1.05 (0.9-1.22), 0.55
Level of Care	HC III	107 (26%)	87 (81%)	1.0	1.0
	HC IV	107 (26%)	74 (70%)	0.85 (0.62-1.15), 0.306	0.8 (0.67-0.94), 0.008
	GH	105(25.6 %)	62 (59%)	0.72 (0.52-1.00), 0.05	0.71 (0.58-0.85), <0.001
	RRH	91 (22%)	76 (84%)	1.02 (0.75-1.40), 0.86	1.01 (0.88-1.16), 0.80
Treatment supporter	No supporter	311 (76.5%)	223 (72%)	1.0	1.0
	At least one	49 (11.2%)	27 (55%)	1.3 (0.87- 1.943), 0.196	1.44 (1.13- 1.83), 0.003
Sex	Male	169 (41.2%)	119 (70%)	1.0	1.0
	Female	241 (58.8%)	179 (75%)	1.06 (0.84-1.33), 0.5	1.04 (0.91-1.2), 0.50

103 CI: Confidence Interval; HC: Health Center; PR: Prevalence Ratio; TB: Tuberculosis

104 **PHASE II: QUALITATIVE**

105 Of the 20 in-depth interviews conducted among a sub-set of adolescents, nine were eligible but
 106 did not participate in 99DOTS, and 11 had engaged with 99DOTS. Overall, 50% (n=10) were
 107 male, 70% (n=14) were 15-19 years of age, 40% (n=8) were living with HIV, and 45% (n=9)
 108 received care at lower-level health facilities (level III or IV). Key informant interviews were
 109 conducted with eight health workers. Among the health workers, 50% (n=4) were female, and

110 three were employed at lower-level health facilities. Themes explaining quantitative findings in
111 the context of facilitators and barriers to the uptake of 99DOTS by adolescents were mapped onto
112 each of the three domains of the COM-B model to elucidate the multifaceted factors that influence
113 the uptake of 99DOTS.

114 **Facilitators of Uptake of 99DOTS**

115

116 ***Capability***

117 Existing technological savviness among adolescents, regardless of age, was a psychological
118 facilitator of the uptake of 99DOTS for many adolescents, who described being attracted to the
119 novel mobile technology and were quickly able to grasp how to use 99DOTS. Similarly,
120 technological comfort also enhanced health worker capability to use 99DOTS. Overall, most
121 participants described that adolescents were comfortable with phones and the 99DOTS
122 technology:

123 *“The digital world, you know adolescents and the digital world...they were*
124 *already interested in phones, and therefore it was easy for them, the adolescents*
125 *were the best people [for the 99DOTS approach] -Healthcare provider, HC III*
126 *health facility*

127

128 ***Opportunity***

129 Caregivers played a key role in supporting opportunities for uptake of 99DOTS by providing
130 phone access and, in some cases, a commitment to support the adolescents in using the system. In
131 addition, many adolescents highlighted that access to clear training and education on the use of
132 99DOTS provided by healthcare providers facilitated the opportunity to participate in the
133 approach.

134 ***Motivation***

135 The desire to recover from tuberculosis was an essential driver of uptake of the 99DOTS among
136 adolescents, irrespective of age and HIV status, as described by an adolescent who participated in
137 99DOTS.

138 *“It [99DOTS] gave me the encouragement that I have to take medicine as my life*
139 *is my life and not anyone else’s; that is it, and I remember some words in Luganda:*
140 *‘For your life to be good’- Adolescent with TB, participated in 99DOTS, 15-19*
141 *years old*

142
143 Most adolescents and healthcare providers said that the 99DOTS novel packaging and design
144 appealed to adolescents and remotely reminded and encouraged them to take their medication.
145 Adolescent participants, in particular, felt the medication packaging was appropriately nondescript
146 and allayed fears about inadvertent disclosure and TB-related stigma. Further, healthcare providers
147 at all levels of care reported that 99DOTS improved their communication with adolescent TB
148 patients in a way that enhanced their ability to care for and communicate with adolescents with
149 TB.

150 *“You know adolescents are very stubborn. First of all, they are faced with stigma, and*
151 *secondly, they are faced with peer issues. They are also faced with the challenge of taking*
152 *treatment in hiding. When 99DOTS is there, you can monitor them and get closer to them*
153 *as they are taking treatment.” -Healthcare provider, GH health facility*

154
155 Some adolescents also reported that they were motivated to use 99DOTS because of the enhanced
156 or better-facilitated access to their healthcare providers that the approach offered.

157

158 **Barriers to Uptake of 99DOTS**

159 *Capability*

160 Low literacy or limited language proficiency in available languages, more common among
161 younger adolescents, impeded the ability to engage with 99DOTS and served as a barrier to uptake
162 for some participants. In addition, healthcare providers further described that low literacy among
163 adolescents increased the time to administer 99DOTS, as they had to provide more explanation
164 and demonstration. This impacted the healthcare providers' ability to fully explain or allow
165 adolescents to engage and consider uptake of the approach.

166 *“For those that knew how to use a phone, it was easy. Maybe for those who have not gone*
167 *to school or do not know how to use a phone...it was hard because you know teaching*
168 *someone how to use a phone when they have never used a phone before--”*- Healthcare
169 provider, GH health facility

170

171 *Opportunity*

172 Limited agency in healthcare decision-making, variable and inconsistent mobile phone access, and
173 connectivity were notable barriers to adolescents' opportunity to engage in 99DOTS. A number of
174 participants who did not engage with 99DOTS described how the approach was explained to their
175 caregiver. Subsequently, the caregivers made the decision regarding enrollment regardless of the
176 adolescents' opinion, as described by an adolescent with TB who did not participate in 99DOTS
177 (age 15-19):

178 *“Yes, I wanted [to participate in 99DOTS] but because my mum was like ‘you will not keep*
179 *up with it [99DOTS]’, I will not manage, I did not use it.”*

180 Although the quantitative analysis did not show any significant difference in uptake by sex, some
181 healthcare providers noted that there was differential access to mobile phones among male and

182 female adolescents, as described by a healthcare provider from an RRH facility: *“Poor access to*
183 *the phone was more for females. Being adolescents, the parents could not allow the girls to use*
184 *phones”*. Adolescent participants described limited or nuanced mobile phone access as a barrier
185 to uptake. While older adolescents were more likely to have their own phone or more regular
186 mobile phone access, the majority of adolescents described reliance on a family member or
187 caregivers’ phone to use 99DOTS:

188 *“My father was not always around. He promised to give me the phone whenever I needed to call.*
189 *He became busy and he worked from far. My mother’s phone was with my grandmother. We did*
190 *not go back to follow-up the process of making phone calls”* -Adolescent with TB, not enrolled
191 on 99DOTS, 10-14 years old

192 **Motivation**

193 Disclosure of TB status was a concern among most adolescent participants regardless of the
194 99DOTS enrollment status. Adolescents who shared or used other people’s phones feared that
195 99DOTS calls or reminder messages could be sent when the phone was with another person to
196 whom they were not ready to disclose their TB status. Some adolescents described this as a de-
197 motivating factor in the uptake of 99DOTS.

198 *“Maybe messages may be tricky because any one can see them. Even phones call for us*
199 *who don’t have phones you may not know when the call will be made. I suggest that we*
200 *agree with health workers about the time they can send a message or call”*- Adolescent
201 with TB, did not participate in 99 DOTS, 15-19 years old

202 Some adolescents felt that they would be subjected to intensified monitoring by agreeing to use
203 99DOTS, with many expressing an underlying fear that healthcare providers would not be happy
204 and would judge those whom the 99DOTS showed as non-adherent.

205 *“They [healthcare providers] would judge you because they know that you are not taking*
206 *your medicine and they can tell that this given patient is not.”* -Adolescent with TB, did
207 not participate in 99 DOTS, 15-19 years old

208 Some healthcare providers described concerns about increased workload with the introduction of
209 the 99DOTS platform.

210 *Hmmm! Some of them [other healthcare providers] liked it, while others saw it as added*
211 *work, and then others did not like it but did it because they had to do it. Others looked at*
212 *it as added work but others liked it, as you know some people like it, but they do not like*
213 *extra work as it that extra work involved.* -Healthcare provider, HC III health facility

214 **DISCUSSION**

215 Digital adherence technologies such as 99DOTS can provide an option for remote TB treatment
216 monitoring using a mobile phone and may be attractive to adolescents. As part of a 99DOTS scale-
217 up across 30 facilities in Uganda, we found high uptake of 99DOTS among adolescents with TB
218 (73%). Uptake was higher than for adults (52%) in the DOT for DAT trial (12). Uptake was higher
219 among older adolescents and those with caregiver involvement and lower at higher-level facilities
220 compared to HC IIIs. Qualitative findings further demonstrate that technological proficiency and
221 literacy, access to training, caregiver involvement, and shared decision making influenced the
222 uptake of 99DOTS. Limited mobile phone access, anticipated TB-related stigma and the workload
223 of healthcare providers in hospitals posed barriers to 99DOTS uptake. Overall, adolescents are
224 capable and motivated to participate in 99DOTS, but barriers linked to age, gender, social support,
225 and health center/provider time and involvement present critical opportunity-related barriers that
226 if addressed could further improve uptake and user experience.

227 Phone access and the ability to use a mobile phone played a role in the capability and opportunity
228 for uptake of 99DOTS among participants in this study. The greater uptake among adolescents 15
229 to 19 years of age may be due to differences in phone accessibility, with more access among older
230 adolescents compared to younger adolescents aged 10 to 14 years. While mobile phone access is
231 widespread, ownership globally increases with age, with significantly higher phone ownership
232 among older adolescents than younger (16); (17). Our qualitative findings also suggested
233 disparate phone ownership and control by sex, with female adolescents potentially having lower
234 phone ownership and control compared to male counterparts, which could impact participation in
235 99DOTS. The findings are consistent with a mixed methods study in Rakai (18), central Uganda,
236 which found that complex gender disparities and control mechanisms may significantly influence
237 adolescent and young women's phone access.

238 Treatment supporters were essential in facilitating the opportunity for the uptake of 99DOTS
239 among adolescents. The interviews revealed that treatment supporters provided additional
240 explanations of 99DOTS to adolescents, were important facilitators of their ability to participate
241 in 99DOTS by ensuring access to their mobile phones, and provided counseling on the use of
242 99DOTS. We found that caregivers can provide critical informational, instructional, and
243 emotional support during TB treatment (19). These findings align with two studies from Peru
244 among adolescents with TB. A qualitative study found that adolescent emotional support and
245 treatment monitoring from caregivers were essential to adherence, and a prospective cohort study
246 found that adolescents with the weakest social support had considerably worse adherence to
247 treatment. Overall, studies have shown that adolescents benefit from the caregiver and parental
248 support to facilitate decision-making and the ability to attend treatment follow-up schedules (3,
249 20, 21). Our findings add to this evidence by demonstrating the multifaceted pathways that
250 treatment support can impact adolescent uptake of an intervention in the TB care setting.

251 Agency in health care decision-making limited adolescent uptake of 99DOTS, although
252 adolescents reported motivation to participate in service of their recovery from TB. Adolescents
253 10 to 17 years are minors in Uganda and often dependent on parents or caregivers for decision
254 support. Our qualitative findings show that these adolescents could have benefitted from the
255 additional explanation about 99DOTS provided to caregivers. The role of caregiver counseling in
256 adolescent decision-making is supported by other studies that focus on the parental role in
257 improving uptake and adherence to TB treatment. A study among adolescents in Uganda suggested
258 that parental sensitization by healthcare providers about TB improved involvement and care during
259 treatment and is a key contributor to adolescent treatment uptake (22). However, our findings also
260 highlight that while parents and caregivers are often facilitators, they may serve as barriers to
261 intervention participation, as some participants in our study described not having the opportunity
262 to decide whether to participate in 99DOTS. While different in context, the potential implications
263 may not be dissimilar from the sexual and reproductive adolescent health decision-making
264 literature, where adolescents may abstain from interventions or services because of the need for
265 parental notification or involvement (23). Our findings demonstrate that an adolescent-centered
266 approach that balances parental and adolescent decision-making and agency is needed to ensure
267 adequate and sustainable enrollment and participation in digital adherence technologies. Both
268 adolescents and healthcare providers raised concerns about inadvertent TB disclosure and stigma
269 as motivational barriers to 99DOTS uptake. TB stigma, whether anticipated or experienced, is a
270 significant concern for adolescents (24), and approaches to address or mitigate this concern must
271 be taken into account as this will determine their uptake of 99DOTS regardless of agency.

272 This study had limitations. First, the study utilized secondary data collected in TB registers, which
273 limited the number of variables evaluated. This was mitigated by conducting qualitative interviews
274 to understand further 99DOTS beyond the variables recorded by the National TB register. Second,

275 as the interviews were conducted after the completion of 99DOTS, only adolescents or their
276 caregivers with working phone numbers or those whose location was known could be invited to
277 participate in the study. However, study team members worked to obtain phone numbers for all
278 individuals in the sampling frame who were selected for participation, including visiting health
279 facilities, to obtain updated telephone information. Finally, these findings represent the
280 experiences within the Kampala region of Uganda and thus may not be generalizable or
281 transferrable to other settings. However, as Uganda and other countries adopt or scale up 99DOTS
282 or similar digital adherence technologies, the themes from the qualitative findings can be helpful
283 in planning and implementation.

284 **CONCLUSION**

285 99DOTS-based treatment supervision had high overall uptake among adolescents treated for
286 pulmonary TB, and healthcare providers were interested in and engaged in using the technology.
287 99DOTS is a promising digital platform for TB treatment adherence among adolescents, who often
288 require tailored treatment approaches. 99DOTS implementation for adolescents can be enhanced
289 with increased access to mobile phones and improved healthcare provider communication with
290 adolescents and their caregivers to facilitate shared treatment decision-making and address TB-
291 related stigma concerns. Policymakers and practitioners should leverage these facilitators and
292 consider strategies to address barriers in the adolescent rollout of digital adherence technologies.

293

294 **METHODS AND MATERIALS**

295 **Study Design**

296 We used a sequential explanatory mixed methods design (25) to quantitatively identify factors
297 associated with the uptake of 99DOTS among adolescents with DS-PTB using cross-sectional data
298 (Phase 1) and further explore these factors in-depth using qualitative semi-structured interviews
299 with adolescents diagnosed with DS-TB and health workers (Phase 2).

300 *Theoretical framework*

301 The Capability, Opportunity, Motivation, and Behavior (COM-B) model is a behavior change
302 framework comprised of three constructs that interact to influence behavior (26). This model posits
303 that to adopt a particular behavior (e.g., uptake of 99DOTS), there must be capability, opportunity,
304 and motivation to perform the behavior: behavior is defined as any action a person takes in
305 response to internal or external events, capability is both physical and psychological ability or
306 capacity to execute a behavior, opportunity is the external factors both physical and social that are
307 associated with undertaking a specific behavior, and motivation is the automatic or reflective
308 mental compulsion to carry out a specific behavioral option amidst alternatives (27).

309 *Study Setting*

310 The DOT to DAT trial and 99DOTS scale-up was conducted at 30 Designated TB treatment Units
311 (DTU) including seven health center IIIs, six health center IVs, and 17 hospitals in the Kampala,
312 Uganda region. These health facilities are located in urban Kampala metropolitan and rural regions
313 with a radius of 280 kilometers outside Kampala. Health center IIIs are located at the sub-county
314 level and offer basic emergency care, while health center IVs are larger and located at health sub-
315 districts and provide comprehensive care in addition to other primary health care services offered
316 at Health center III. Hospitals include both general and regional referral hospitals. The complexity

317 of cases handled increases from Health Center III to regional referral hospitals. Health facilities
318 were selected based on their TB notification rates in the Kampala region (MOH, 2020).

319 *Study Population*

320 Adolescents 10-19 years of age with DS-PTB treated with adult fixed-dose combination (2 RHZE;
321 4RH) at the 30 DOT to DAT trial and 99DOTS scale-up TB treatment sites in Uganda from July
322 2020-June 2021 were eligible for inclusion in quantitative analyses. All adolescents from the
323 quantitative sample and all health workers were eligible for qualitative semi-structured in-depth
324 interviews.

325 *Sample size*

326 The sample size was fixed (N=410) based on the number of adolescents treated for TB at
327 participating health centers during the 99DOTS scale-up project period. Drawing upon maximum
328 variation sampling on the primary descriptors of interest from the quantitative data (age, sex, HIV
329 status, and level of care), a sample size of 20 adolescents was targeted for qualitative in-depth
330 interviews and eight health workers for key informant interviews (28). The study anticipated
331 saturation would be achieved, given that respondents were relatively homogenous within their
332 sampling categories (28). During qualitative data collection, study data was monitored through
333 weekly team calls and debriefing to assess saturation.

334 **Phase 1 (Quantitative)**

335 *Sampling*

336 Sampling for the DOT to DAT trial is described elsewhere (12). All adolescents 10 to 19 years
337 who were initiated on anti-TB treatment during the scale-up phase of the DOT to DAT study were
338 eligible for inclusion in the quantitative analysis. Adolescents who had incomplete baseline
339 treatment records were excluded because the study could not ascertain the treatment supervision

340 approach used. The study also excluded those diagnosed with TB osteomyelitis, meningitis, or
341 multi-drug resistant TB because they were not eligible for enrollment on 99DOTS.

342 *Data collection*

343 Routine patient data from TB treatment centers entered into the National TB register for all study
344 sites was abstracted by study staff into a REDCap database (29). The DOT to DAT trial collected
345 additional data on patient age, weight, height, address, telephone number, diagnostic and treatment
346 facility, clinical status, HIV status, treatment issued, and TB treatment outcomes.

347 *Study Variables*

348 Independent variables

349 Independent variables included adolescent social and demographic characteristics and health
350 system factors that may influence the uptake of 99DOTS: sex, level of health care, presence of
351 treatment supporter at diagnosis, HIV status, and type of TB disease being managed. Sex, HIV
352 serostatus, and category of TB disease were classified as binary categorical variables. Age in years
353 was categorized as either “younger adolescents” (10 to 14 years) or “older adolescents” (15 to 19
354 years), and level of health care was classified as a categorical, ordinal variable with health centers
355 (levels III, IV), hospitals, and regional referral hospitals as different levels of care in-line with
356 determinations by the Ministry of Health in Uganda(30).

357 Dependent variables

358 The primary outcome variable was the uptake of 99DOTS. We defined the primary outcome as
359 binary: received 99DOTS or routine CB-DOT.

360 *Statistical Analyses*

361 We used descriptive statistics to summarize participant characteristics. We used a modified poisson
362 regression (31) to determine the association between age, sex, level of health care, HIV serostatus,
363 type of TB disease, and availability of a treatment supporter, with uptake of 99DOTS. The final
364 multivariate model was fitted with variables based on the extant literature (age, sex) or factors
365 associated with uptake of 99DOTS at $p < 0.20$ in univariate analysis (32). Further, collinearity
366 within the predictor variables was ruled out, and a stepwise approach was used to build the
367 multivariable model and model fitness evaluated (Pearson's chi-squared p -value=0.87). Data were
368 analyzed using Stata version 14.3 (StataCorp, College Station) (33).

369 **Phase 2 (Qualitative)**

370 *Sampling*

371 Using a sampling frame of adolescent patients treated for DS-PTB at participating 99DOTS scale-
372 up TB treatment centers, we aimed to recruit approximately even numbers of adolescents who
373 participated in 99DOTS and adolescents who declined to participate in 99DOTS. In addition, the
374 health workers who managed participating TB treatment centers and provided care to adolescents
375 for TB during the study period were purposively approached for participation in key informant
376 interviews.

377 *Data collection*

378 In-depth interviews (IDIs) were conducted by experienced Ugandan interviewers using semi-
379 structured guides. Interviewers received additional training on the study protocol and adolescent
380 engagement. Interview guides were developed to elicit experiences with 99DOTS, including
381 barriers and facilitators to enrollment and its use. Questions were informed by DOT to DAT trial
382 findings and the COM-B model (27) and explored perceptions of 99DOTS, understanding of
383 99DOTs, and factors that might influence 99DOTS uptake. In addition to these questions, health

384 workers were asked for their perceptions of the training they received and their use of 99DOTS.
385 IDIs with adolescents and health workers were conducted by trained qualitative interviewers in the
386 participant's language of choice (English, Luganda, or Lusoga). Interviews were held at health
387 facilities or by telephone, per participant preference. Interviews lasted between 30 and 60 minutes,
388 were audio-recorded, transcribed verbatim, translated into English (as necessary), and uploaded
389 into Dedoose version 4.3 for data management, coding, and analysis (34).

390

391 *Analysis*

392 We utilized a thematic analysis approach to explore pre-defined areas of interest related to
393 99DOTS uptake from the quantitative findings and prior theoretical frameworks while allowing
394 detailed and new insights and themes to emerge from the data (35). The study analysis team
395 developed an initial codebook consisting of a-priori codes informed by quantitative findings and
396 the COM-B domains. Study team members read all transcripts and open-coded a subset of
397 transcripts in parallel to further identify codes. The codebook was iteratively refined during the
398 initial data familiarization and coding process, with inductive codes added to reflect emergent
399 themes. When the codebook was finalized, all codes were systematically applied across all the
400 transcripts, starting with double coding completed on a subset of four transcripts until consensus
401 on code domains and definitions was reached among analysis team members. Following coding,
402 data were organized into a chart format for each key theme that included summaries of different
403 barriers and facilitators of uptake of 99DOTS among adolescents with respective illustrative
404 quotes. Themes were iteratively compared and explored across participant types and sub-
405 categories (age, sex, HIV status) to facilitate the identification of potential explanations for
406 findings from the quantitative analysis. The themes were further situated within the COM-B model

407 (26, 27) to provide a framework to inform understanding of uptake of 99DOTS in the context of
408 barriers and facilitators.

409 **Author Contributions:** Conceptualization, A.C, A.K, D.J, A.K; Methodology, A.C, A.K, D.J;
410 Validation A.C, A.K, D.J; Investigation, P.W, N.W, J.N, A.K, R.C, L.K; Formal Analysis P.W,
411 N.W, J.N, A.K; Writing-Original Draft Preparation, P.W, N.W, J.N ; Writing-Review & Editing,
412 P.W, N.W, J.N , E.W, A. A.C, A.K, D.J; Supervision, A.C, A.K, D.J, N.W, J.N , E.W ; Project
413 Administration, A.C, A.K, D.J, N.W, J.N, E.W; Funding Acquisition, A.C, A.K.

414 **Funding:** This study was supported by the Stop TB Partnership’s TB REACH initiative, grant
415 number STBP/TBREACH/GSA/W6-37 (AC, AK), which is funded by the Government of Canada,
416 the Bill & Melinda Gates Foundation, the United States Agency for International Development
417 and Makerere University College of Health Sciences -University of carlifornia Berkeley-Yale
418 Pulmonary Complications of AIDS Research Training (PART) Program, NIH D43TW009607,
419 from the Forgaty International Center (FIC).

420 **Conflict of interest:** The Authors declare no conflict of interest.

421 **Ethics Standards Disclosure:** The study obtained approval from the Makerere University School
422 of Public Health Research and Ethics Committee to conduct the sub-study (Protocol #630) and
423 Uganda National Council for Science and Technology (HS 2436). Further, informed consent was
424 obtained from all participants for in-depth and key informant interviews and assent for adolescents
425 under 18 years old.

427 **References**

- 428 1. WHO. Global Tuberculosis Report World Health Organization; 2022.
- 429 2. Sawyer SM, Azzopardi PS, Wickremarathne D, Patton GC. The age of adolescence. *The lancet child*
430 & adolescent health. 2018;2(3):223-8.
- 431 3. Leddy AM, Jaganath D, Triasih R, Wobudeya E, Bellotti de Oliveira MC, Sheremeta Y, et al. Social
432 determinants of adherence to treatment for tuberculosis infection and disease among children,
433 adolescents, and young adults: a narrative review. *Journal of the Pediatric Infectious Diseases Society*.
434 2022;11(Supplement_3):S79-S84.
- 435 4. Snow KJ, Cruz AT, Seddon JA, Ferrand RA, Chiang SS, Hughes JA, et al. Adolescent tuberculosis.
436 *The Lancet Child & Adolescent Health*. 2020;4(1):68-79.
- 437 5. Wobudeya E, Jaganath D, Sekadde MP, Nsangi B, Haq H, Cattamanchi A. Outcomes of empiric
438 treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015. *BMC public health*. 2019;19(1):1-6.
- 439 6. Laycock KM, Enane LA, Steenhoff AP. Tuberculosis in adolescents and young adults: Emerging data
440 on TB transmission and prevention among vulnerable young people. *Tropical Medicine and Infectious*
441 *Disease*. 2021;6(3):148.
- 442 7. MOH. The Annual Health sector Performance report Uganda Financial Year 2021/22. 2022.
- 443 8. Mulongeni P, Hermans S, Caldwell J, Bekker L-G, Wood R, Kaplan R. HIV prevalence and
444 determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. *PLoS*
445 *One*. 2019;14(2):e0210937.
- 446 9. WHO. Framework for implementing the “End TB Strategy” in the African Region 2016-2020. 2017.
- 447 10. MOH. National Tuberculosis and leprosy control strategy 2020. In: Health Mo, editor. Republic of
448 Uganda2020. p. 37-9.
- 449 11. Subbaraman R, de Mondesert L, Musiimenta A, Pai M, Mayer KH, Thomas BE, et al. Digital
450 adherence technologies for the management of tuberculosis therapy: mapping the landscape and
451 research priorities. *BMJ global health*. 2018;3(5):e001018.
- 452 12. Cattamanchi A, Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, et al. Digital
453 adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial
454 in Uganda. *PLoS medicine*. 2021;18(5):e1003628.
- 455 13. Leddy A, Ggita J, Berger CA, Kityamuwesi A, Sanyu AN, Tinka LK, et al. Barriers and facilitators to
456 implementing a digital adherence technology for tuberculosis treatment supervision in Uganda:
457 qualitative study. *Journal of Medical Internet Research*. 2023;25:e38828.
- 458 14. Zawedde-Muyanja S, Manabe YC, Cattamanchi A, Castelnuovo B, Katamba A. Patient and health
459 system level barriers to and facilitators for tuberculosis treatment initiation in Uganda: a qualitative study.
460 *BMC health services research*. 2022;22(1):831.
- 461 15. Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka LK, et al. Study protocol and
462 implementation details for a pragmatic, stepped-wedge cluster randomised trial of a digital adherence
463 technology to facilitate tuberculosis treatment completion. *BMJ open*. 2020;10(11):e039895.
- 464 16. Bhandari DJ, Pandya YP, Sharma DB. Smartphone use and its addiction among adolescents in the
465 age group of 16–19 years. *Indian journal of community medicine: official publication of Indian Association*
466 *of Preventive & Social Medicine*. 2021;46(1):88.
- 467 17. Lenhart A. Teens and mobile phones over the past five years: Pew Internet looks back. *Pew*
468 *Internet & American Life Project* Washington, DC; 2009.
- 469 18. Basmajian A, Kreniske P, Moore EV, Spindler E, Nalugoda F, Nakyanjo N, et al. Gendered access to
470 digital capital and mobile phone ownership among young people in Rakai, Uganda. *Culture, Health &*
471 *Sexuality*. 2023;25(5):648-63.
- 472 19. Bauer JE. *Health Behavior and Health Education: Theory, Research, and Practice* (3rd edn.).
473 Medknow; 2004.

- 474 20. Chiang SS, Senador L, Altamirano E, Wong M, Beckhorn CB, Roche S, et al. Adolescent, caregiver
475 and provider perspectives on tuberculosis treatment adherence: a qualitative study from Lima, Peru. *BMJ*
476 *open*. 2023;13(5):e069938.
- 477 21. Chiang SS, Tanzer JR, Starke JR, Friedman JF, Roman Sinche B, León Ostos K, et al. Identifying
478 adolescents at risk for suboptimal adherence to tuberculosis treatment: A prospective cohort study. *PLOS*
479 *Global Public Health*. 2024;4(2):e0002918.
- 480 22. Omongot S, Muttamba W, Najjingo I, Baruch Baluku J, Kitaka S, Turyahabwe S, et al. Strategies to
481 resolve the gap in adolescent tuberculosis care at four health facilities in Uganda: The teenager's TB pilot
482 project. *PLoS One*. 2024;19(4):e0286894.
- 483 23. Reddy DM, Fleming R, Swain C. Effect of mandatory parental notification on adolescent girls' use
484 of sexual health care services. *Jama*. 2002;288(6):710-4.
- 485 24. Atkins S, Heimo L, Ribas Closa M, Vanleeuw L, Wambi P, Chenciner L, et al. Background question
486 1: The socioeconomic impact of tuberculosis on children, adolescents and families: A scoping review. *WHO*
487 *consolidated guidelines on tuberculosis*. 2022:37.
- 488 25. Ivankova NV, Creswell JW, Stick SL. Using mixed-methods sequential explanatory design: From
489 theory to practice. *Field methods*. 2006;18(1):3-20.
- 490 26. Michie S, Atkins L, West R. The behaviour change wheel. A guide to designing interventions 1st ed
491 Great Britain: Silverback Publishing. 2014;1003:1010.
- 492 27. West R, Michie S. A brief introduction to the COM-B Model of behaviour and the PRIME Theory
493 of motivation [v1]. *Qeios*. 2020.
- 494 28. Suri H. Purposeful sampling in qualitative research synthesis. *Qualitative research journal*.
495 2011;11(2):63-75.
- 496 29. Patridge EF, Bardyn TP. Research electronic data capture (REDCap). *Journal of the Medical Library*
497 *Association: JMLA*. 2018;106(1):142.
- 498 30. Ministry of Health RoU. The Second National Health Policy 2010 [Available from:
499 <https://library.health.go.ug/sites/default/files/resources/Second%20National%20Health%20Policy%202010.pdf>.
500 [010.pdf](https://library.health.go.ug/sites/default/files/resources/Second%20National%20Health%20Policy%202010.pdf).
- 501 31. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical
502 comparison of models that directly estimate the prevalence ratio. *BMC medical research methodology*.
503 2003;3:1-13.
- 504 32. Chen M-H, Dey DK. Variable selection for multivariate logistic regression models. *Journal of*
505 *Statistical Planning and Inference*. 2003;111(1-2):37-55.
- 506 33. Gafoor R. *A Comprehensive Guide to Coding and Programming in Stata*: CRC Press; 2024.
- 507 34. Andrade LR, Costa AP, Linhares RN, de Almeida CA, Reis LP, editors. *Qualitative data analysis*
508 *software packages: An integrative review*. *World Conference on Qualitative Research*; 2018: Springer.
- 509 35. Swain J. *A hybrid approach to thematic analysis in qualitative research: Using a practical example*.
510 *Sage research methods*. 2018.

511